Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T15:51:22.167Z.
Calculation as of: 2026-10-06T15:51:22.167Z.
Quote observation: 2026-10-06T15:49:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c1a6838803f42d6ea125a2cca62df7e150df7eb7d5f2d1fff74d5c1a91b3d340
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$489.40M
Operating Cash Flow Yield
8.41%
TTM Avg
13.05%
3Y Avg
17.35%
5Y Avg
16.73%
Market Cap
$497.95M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$480.04M
Operating Cash Flow Yield
N/A
TTM Avg
18.97%
3Y Avg
18.89%
5Y Avg
14.32%
Market Cap
$475.66M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$476.61M
Operating Cash Flow Yield
0.51%
TTM Avg
0.89%
3Y Avg
1.82%
5Y Avg
1.82%
Market Cap
$510.83M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$473.27M
Operating Cash Flow Yield
N/A
TTM Avg
4.04%
3Y Avg
4.04%
5Y Avg
4.04%
Market Cap
$514.69M
Operating Cash Flow Yield
0.27%
TTM Avg
0.34%
3Y Avg
0.34%
5Y Avg
0.34%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $490.95M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $489.40M | 8.41% | 13.05% | 17.35% | 16.73% |
| Oculis Holding AG (OCS)vs › | $497.95M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $480.04M | N/A | 18.97% | 18.89% | 14.32% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $475.66M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $476.61M | 0.51% | 0.89% | 1.82% | 1.82% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.83M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $473.27M | N/A | 4.04% | 4.04% | 4.04% |
| 908 Devices Inc. (MASS)vs › | $514.69M | 0.27% | 0.34% | 0.34% | 0.34% |
| Kamada Ltd. (KMDA)vs › | $475.69M | 7.57% | 6.58% | 6.94% | 6.76% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
